⚠️ This provider averages 876 services per working day — physically unusual for an individual practitioner
Based on 1.5M total services over 7 years (250 working days/year). Learn about impossible service volumes →
This provider's $32.1M in total Medicare payments ranks in the 99th percentile of Hematology-Oncology providers nationally.
Averaging 876 services per working day raises questions about billing patterns.
Medicare payments to this provider grew 25994% from 2017 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 6096% in 2018
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2017 | $164.63 | $83.71 | 1.97x | $80.92 | $26.5K | 317 | 7 |
| 2018 | $46.81 | $26.49 | 1.77x | $20.32 | $1.6M | 62.1K | 28 |
| 2019 | $49.14 | $20.62 | 2.38x | $28.52 | $3.6M | 174.4K | 39 |
| 2020 | $47.48 | $18.56 | 2.56x | $28.92 | $4.0M | 214.9K | 37 |
| 2021 | $49.96 | $19.75 | 2.53x | $30.21 | $7.9M | 401.8K | 45 |
| 2022 | $53.18 | $20.67 | 2.57x | $32.51 | $8.0M | 385.2K | 44 |
| 2023 | $61.27 | $23.48 | 2.61x | $37.79 | $6.9M | 294.8K | 43 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 278.2K | $11.5M | $41.48 | 2.46x |
| J9299 | Injection, nivolumab, 1 mg | 202.0K | $4.6M | $22.57 | 2.38x |
| J9022 | Injection, atezolizumab, 10 mg | 54.5K | $3.4M | $61.62 | 2.56x |
| J9173 | Injection, durvalumab, 10 mg | 47.4K | $2.9M | $61.02 | 2.47x |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 43.9K | $1.6M | $36.89 | 2.49x |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 17.4K | $1000.0K | $57.50 | 2.49x |
| J0897 | Injection, denosumab, 1 mg | 58.3K | $934.0K | $16.01 | 2.51x |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 6.4K | $735.0K | $114.98 | 2.57x |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 7.5K | $688.9K | $91.59 | 2.60x |
| J9035 | Injection, bevacizumab, 10 mg | 9.6K | $601.2K | $62.88 | 1.99x |
| J2505 | Injection, pegfilgrastim, 6 mg | 175 | $559.3K | $3.2K | 2.33x |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 3.3K | $526.6K | $161.34 | 3.01x |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 12.8K | $446.7K | $34.79 | 2.71x |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 151.3K | $371.7K | $2.46 | 3.63x |
| J9145 | Injection, daratumumab, 10 mg | 8.5K | $339.0K | $39.84 | 1.78x |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | 1.9K | $250.1K | $130.54 | 2.55x |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 5.0K | $223.0K | $44.41 | 2.59x |
| Q5120 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg | 1.2K | $219.0K | $189.14 | 2.83x |
| J9041 | Injection, bortezomib, 0.1 mg | 6.9K | $103.6K | $15.11 | 4.51x |
| J0185 | Injection, aprepitant, 1 mg | 53.3K | $77.1K | $1.45 | 2.74x |
This provider submits charges 2.5 times higher than what Medicare actually pays.
A markup ratio of 2.5x means for every $100 Medicare pays, this provider initially charges $250. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Hematology-Oncology providers in MD for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| David Smith, MD | Easton, MD | $48.3M | ✓ Clear |
| Frederick Smith, M.D. | Chevy Chase, MD | $33.7M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data